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Background: Asthma is caused by both environmental and genetic factors. The ADRB2 gene, which encodes the
beta 2-adrenergic receptor, is one of the most extensively studied genes with respect to asthma prevalence and
severity. The Arg16Gly (+46A > G) and Gln27Glu (+79C > G) polymorphisms in the ADRB2 gene cause changes in
the amino acids flanking the receptor ligand site, altering the response to bronchodilators and the risk of asthma
through complex pathways. The ADRB2 polymorphisms affect beta-adrenergic bronchodilator action and are a tool
to identify at-risk populations.
Objective: To determine the frequency of these two polymorphisms in allergic asthma patients and healthy
subjects and to correlate these data with the occurrence and severity of asthma.
Methods: Eighty-eight allergic asthma patients and 141 healthy subjects were included in this study. The ADRB2
polymorphisms were analyzed using the amplification-refractory mutation system – polymerase chain reaction
(ARMS-PCR) technique. The statistical analysis was performed with the SPSS 21.0 software using the Fisher’s Exact
and χ2 tests.
Results: The ADRB2 polymorphisms were associated with asthma occurrence. The Arg16Arg, Gln27Gln and
Gln27Glu genotypes were risk factors; the odds ratios were 6.782 (CI = 3.07 to 16.03), 2.120 (CI = 1.22 to 3.71) and
8.096 (CI = 3.90 to 17.77), respectively. For the Gly16Gly and Glu27Glu genotypes, the odds ratios were 0.312
(CI = 0.17 to 0.56) and 0.084 (CI = 0.04 to 0.17), respectively. The haplotype analysis showed that there were
associations between the following groups: Arg16Arg-Gln27Gln (OR = 5.108, CI = 1.82 to 16.37), Gly16Gly-Glu27Glu
(OR = 2.816, CI = 1.25 to 6.54), Arg16Gly-Gln27Glu (OR = 0.048, CI = 0.01 to 0.14) and Gly16Gly-Gln27Glu (OR = 0.1036,
CI = 0.02 to 0.39). The polymorphism Gln27Glu was associated with asthma severity, as the Gln27Gln genotype was
a risk factor for severe asthma (OR = 2.798, CI = 1.099 to 6.674) and the Gln27Glu genotype was a protective factor
for mild (OR = 3.063, CI = 1.037 to 9.041) and severe (OR = 0.182, CI = 0.048 to 0.691) asthma.
Conclusions: The Arg16Gly and Gln27Glu polymorphisms in the ADRB2 gene are associated with asthma presence
and severity.
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Asthma is a chronic inflammatory disease of the airways
defined by clinical, physiological and pathological char-
acteristics. The main traits of allergic asthma in children
are shortness of breath, wheezing, obstruction and inflam-
mation of airways, and atopy [1]. Genetically, asthma is a
complex disease in which multiple genes interact among
themselves and with the environment [1].
Asthma affects approximately 300 million people world-
wide (1 to 18% of the population in different countries)
[2,3] and is associated with 250,000 deaths per year. In
Brazil, 20% of the population is affected, with approxi-
mately 350,000 hospitalizations per year or 2.3% of the
hospital admissions in the Public Health System [4].
Asthma-related mortality has been growing over the last
10 years but does not correlate with disease prevalence.
Asthma causes 5 to 10% of the respiratory-related deaths,
with a high number of deaths occurring at home [4].
There are several factors that influence the develop-
ment of asthma, including genes that predispose an indi-
vidual to atopy and airway hyperresponsiveness; obesity;
sex; and environmental causes, such as allergens (house
dust mites, animal fur, and fungi), viral infections, occu-
pational sensitizers, tobacco smoke, air pollution and
eating habits. Additionally, some immunological charac-
teristics, such as immune system maturation and the
number of exposures to infectious agents during the first
years of life, are factors that affect the risk of developing
asthma. Another characteristic linked to an increased
risk of asthma is ethnicity, which reflects vast genetic
differences as well as significant social and economic
variations that affect exposure to allergens and access to
health services [1,5-10].
Asthma severity is assessed by analyzing the frequency
and intensity of symptoms and examining pulmonary
function. Based on these criteria, asthma is classified as
either intermittent or persistent asthma, the latter of
which can be mild, moderate or severe [1].
The pathophysiological characteristic present in asth-
matic patients is bronchial inflammation, which is the
result of complex interactions between the inflammatory
cells, cell-derived mediators, and airway cells [11].
An important factor studied in asthma-related research
is the beta-2-adrenergic receptor, which is encoded by the
ADRB2 gene [12]. The ADRB2 gene is a small gene on
chromosome 5q31-q32 [13], a region genetically linked to
asthma [14]. Nine coding polymorphisms were originally
described in the ADRB2 gene, including four that cause
non-synonymous changes in the amino acid sequence
(Gly16Arg, Gln27Glu, Val34Met and Thr164Ile).
The β2 receptors (β2-AR) are widely expressed in the
respiratory tract, particularly in the airway smooth mus-
cles [12,15-17]. They are members of a family of seven-
transmembrane receptors [18] and are 413 amino acidslong [19]. Once activated, the most clinically relevant ef-
fect of the β2-ARs in the pulmonary smooth muscle is
relaxation, which may be caused by β2-AR agonists.
Chronic exposure to these agonists leads to a significant
reduction in the number of β2-ARs on the cell surface
[16,17]. This down-regulation is reflected in vivo as a
tolerance to the effects of the β2-AR agonists [20-24].
In airway smooth muscle cells, the β2-AR agonists ac-
tivate adenylyl cyclase through membrane-coupled G-
proteins; this activation increases the intracellular cAMP
(cyclic adenosine monophosphate) concentration and re-
laxes the airway tonus [25]. The β2-AR agonists may
also affect Ca2+ and K+ channels in smooth muscles and
lead to relaxation independently of cAMP [26].
The two most frequent deleterious polymorphisms in
the ADRB2 gene are Arg16Gly (+46A >G; rs1042713) and
Gln27Glu (+79C >G; rs1042714). The Arg16Gly and
Gln27Glu polymorphisms are near the receptor’s ligand-
binding site [27]. The frequency of Gly16 is greater than
that of Arg16, which is considered the normal allele. The
allelic frequency described for the Arg16 variant ranges
from 67% to 72% in different populations [28,29].
In the Brazilian population, to the best of our know-
ledge, there are no studies on asthma and the frequency
of the Arg16Gly and Gln27Glu polymorphisms that take
into account asthma risk and clinical severity. Therefore,
our study included asthma patients and healthy subjects,
and the associations between both groups and each
polymorphism were assessed during the same analysis.
The clinical evaluation of asthma severity was associated
with the Arg16Gly and Gln27Glu polymorphisms.
Methods
Patients and healthy controls
A cross-sectional prospective study including 88 asthmatic
patients was conducted at the Pediatric Pulmonology
Clinic at the University Hospital.
The mean age was 10.38 (±2.93) years with a range of
7 to 16 years. All patients enrolled had allergic asthma
according to the GINA criteria [1]. The allergy classifica-
tion was defined by co-occurrence with asthma, atopic
dermatitis, a positive skin test in response to allergens
(dust mites, fungi, or house dust components), increased
IgE serum levels, greater than 4% eosinophils in the per-
ipheral blood in the absence of parasites and clinical his-
tory. All patients were subjected to three parasitological
stool examinations three months prior to the onset of the
study and were treated with albendazole as necessary.
The control group was composed of 141 healthy subjects
ranging in age from 18 to 25 years who donated blood at
the Unicamp University Hospital. In our data, all controls
were examined for allergic asthma and a family history of
asthma. In the case of a family history of asthma, the sub-
ject was excluded from our control group.
Table 1 Association of ADRB2 polymorphisms [Arg16Gly (c.46A > G) and Gln27Glu (c.79C > G)] with asthma risk
Polymorphism Genotype Patient Control OR 95% CI
Arg16Gly (c.46A > G) 1,2 Homozygous Arg16 28 9 6.782 3.07-16.03
Heterozygous 38 59 1.056 0.61-1.81
Homozygous Gly16 22 73 0.312 0.17-0.56
Total 88 141
Gln27Glu(c.79C > G) 3,4 Homozygous Gln27 41 41 2.120 1.22-3.71
Heterozygous 36 11 8.096 3.90-17.77
Homozygous Glu27 11 89 0.084 0.04-0.17
Total 88 141
ADR2 = alpha2-adrenergic receptor; Arg = arginine; Gly = Glycine; Gln = Glutamine; Glu = Glutamic acid; A = Adenine; G = Guanine; T = Thymine; OR = Odds Ratio;
CI = Confidence Interval.
Hardy-Weinberg equilibrium was calculated using the OEGE tool (http://www.oege.org/software/hardy-weinberg.html), being: (1 - patient) χ2 = 1.54, p-value > 0.05;
(2 - control) χ2 = 0.48, p-value > 0.05; (3 - patient) χ2 = 0.41, p-value > 0.05; (4 - control) χ2 = 95.62, p-value < 0.001.
The OR was calculated using the Open-Epi tool (http://www.openepi.com). The OR and 95% CI values were obtained using the Mild-P test. For all data analyzed,
α = 0.05 was used. The significant p-values are in bold.
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Arg16Gly and Gln27Glu polymorphism analyses
Genomic DNA was extracted from the venous blood
samples using phenol-chloroform. The DNA concentra-
tion was determined using a GE NanoVue™ Spectropho-
tometer (GE Healthcare Biosciences, Pittsburgh, USA),
and 50 ng/mL of each sample was used for the analysis.
Polymorphism analysis of the ADRB2 gene was per-
formed by the polymerase (PCR) allele specific (ARMS) re-
action [30,31]. Four reactions were performed (ARMS1a,Table 2 Association of ADRB2 polymorphism [Arg16Gly




Patient Control OR 95% CI
Gly16 – Gln27 1 19 23 1.411 0.71-2.79
Arg16 – Glu27 1 10 0 - -
Arg16 – Gln27 0 14 5 5.108 1.82-16.37
Gly16 – Glu27 2 17 11 2.816 1.25-6.54
Het16 – Gln27 0 10 12 1.376 0.55-3.38
Het16 – Glu27 1 9 0 - -
Het16 – Het27 0 3 60 0.048 0.01-0.14
Arg16 – Het27 0 4 4 1.627 0.36-7.39
Gly16 – Het27 1 2 26 0.1036 0.02-0.39
ADRB2 = alpha2-adrenergic receptor; Arg = arginine; Gly = Glycine;
Gln = Glutamine; Glu = Glutamic acid; A = Adenine; G = Guanine; T = Thymine;
Het = heterozygotes; OR = Odds Ratio; CI = Confidence Interval.
*The groups were created by counting each homozygous guanine allele at the
Arg16Gly (c.46A > G) and Gln27Glu (c.79C > G) polymorphisms: (0) Arg16Arg +
Gln27Gln genotype combination; (1) Gly16Gly or Glu27Glu genotype presence;
(2) Gly16Gly + Glu27Glu genotype combination.
The OR was calculated using the Open-Epi tool (http://www.openepi.com).
The OR and 95% CI values were obtained using the Mild-P test. For all data
analyzed, α = 0.05 was used. The significant p-values are in bold.ARMS2a, ARMS1b and ARMS2b), each containing a com-
mon primer (5′-AGG CCC ATG ACC AGA TCA GCA
CAG GCC AG-3′) and one allele-specific primer [ARMS1a
(5′- ACG GCA GCG CCT TCT TGC TGG CAC CCA
AAA-3′), ARMS2a (5′-ACG GCA GCG CCT TCT TGC
TGG CAC CCA AAG-3′), ARMS1b (5′-GCC ATG CGC
CGG ACC ACG ACG TCA CGC ATC-3′) and ARMS2b
(5′-GCC ATG CGC CGG ACC ACG ACG TCA CGC
AAG-3′)]. All four reactions were performed under the
same conditions. Each 10 μL reaction contained 1 × 4 PCR
buffer, 200 μM of dNTPs, 5.0 nM of MgCl2, 0.4 U of Taq
polymerase, 0.2 pmol of each primer and 1.0 μL (approxi-
mately 50 ng) of genomic DNA.
The PCR amplification conditions consisted of 5 mi-
nutes at 94°C followed by 35 cycles of 94°C for 1 minute,
60°C (46A or G, 16Arg or Gly) or 67°C (70C or G, 27
Gln or Glu), and 72°C for 1 minute followed by 72°C for
10 minutes.
The amplicons were subjected to electrophoresis on a
12% acrylamide gel and stained with ethidium bromide.
Statistical analysis
Statistical analysis was performed using the software
SPSS (Statistical Package for the Social Sciences) version
21.0 (Armonk, NY: IBM Corp), Open Epi [32] and R ver-
sion 2.12 (Comprehensive R Archive Network, 2011). The
statistical power calculation for the sample was performed
using the GPOWER 3.1 software [33] and demonstrated
statistical power above 80% for the analysis conducted. An
alpha level of 0.05 was used in all of the data analyses.
The Fisher’s Exact and chi-squared (χ2) tests were per-
formed to determine the association between the poly-
morphisms analyzed and the presence and severity of
asthma.
The Hardy-Weinberg equilibrium was calculated using the
Online Encyclopedia for Genetic Epidemiology (OEGE) soft-
ware (http://www.oege.org/software/hardy-weinberg.html).
Table 3 Association of ADRB2 polymorphisms [Arg16Gly
(c.46A > G) and Gln27Glu (c.79C > G)] with asthma risk
based on the presence of Guanine alleles
Genotypes groups* Patient Control OR 95% CI
0 31 81 0.405 0.23-0.70
1 40 49 1.562 0.90-2.70
2 17 11 2.816 1.25-6.54
ADRB2 = alpha2-adrenergic receptor; Arg = arginine; Gly = Glycine;
Gln = Glutamine; Glu = Glutamic acid; A = Adenine; G = Guanine; T = Thymine;
OR = Odds Ratio; CI = Confidence Interval.
*The groups were created by counting each homozygous guanine allele at the
Arg16Gly (c.46A > G) and Gln27Glu (c.79C > G) polymorphisms: (0) Arg16Arg +
Gln27Gln genotype combination; (1) Gly16Gly or Glu27Glu genotype presence;
(2) Gly16Gly + Glu27Glu genotype combination.
The OR was calculated using the Open-Epi tool (http://www.openepi.com). The
OR and 95% CI values were obtained using the Mild-P test. For all data
analyzed, α = 0.05 was used. The significant p-values are in bold.
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gram was used [33]. In the calculation, we considered the
minor allele frequency (MAF) to establish the sample size.
According to the NCBI (National Center for Biotechnology
Information - http://www.ncbi.nlm.nih.gov/) database,
the frequencies of the A and C alleles at the 46A >G and
79C >G polymorphisms were 0.471 and 0.238, respect-
ively. With the frequency of 0.238, α = 0.05 and β = 0.80,
the power calculation estimates the patient sample size
should be 193 patients based on using a χ2 test for the
comparisons to be performed. In our study, we included
229 patients and controls and with our population obtained
a β-error of 0.846.Table 4 Association of asthma severity with ADRB2 polymorp
Severity Arg16Gly (c.46A > G) p
Arg16Arg OR (95% CI) Arg16Gly OR (95%
Severe 14 (37.8%) 1.258 (0.508 - 3.114) 3 (8.1%) 0.25 (0.064 -
Moderate 7(33.3%) 0.909 (0.319 - 2.587) 5 (23.8%) 1.625 (0.484 -
Mild 8 (32%) 0.829 (0.306 - 2.246) 7 (28%) 2.431 (0.771 -
Gln27Glu (c.79C > G) p
Gln27Gln OR (95% CI) Gln27Glu OR (95%
Severe 25 (67.6%) 2.708 (1.099 - 6.674) 3 (8.1%) 0.182 (0.048 -
Moderate 10 (47.6%) 0.701 (0.26 - 1.892) 6 (28.6%) 1.667 (0.534 -
Mild 10 (40%) 0.438 (0.168 - 1.141) 9 (36%) 3.063 (1.037 -
Arg16Gly (c.46A > G) and Gln27Glu (c.79C >
0 OR (95% CI) 1 OR (95%
Severe 12 (32.4%) 0.571 (0.232 - 1.406) 21 (56.8%) 1.706 (0.712 -
Moderate 9 (42.9%) 1.188 (0.435 - 3.241) 10 (47.6%) 0.909 (0.338 -
Mild 12 (48%) 1.626 (0.629 - 4.205) 10 (40%) 0.581 (0.224 -
ADRB2 = alpha2-adrenergic receptor; Arg = arginine; Gly = Glycine; Gln = Glutamine;
CI = Confidence Interval.
*The groups were created by counting each homozygous guanine allele at the Arg
Gln27Gln genotype combination; (1) Gly16Gly or Glu27Glu genotype presence; (2) G
The OR was calculated using the Open-Epi tool (http://www.openepi.com). The OR
value is shown. For all data analyzed, α = 0.05 was used. The significant p-values areTo evaluate the genetic interactions among the polymor-
phisms in our sample, we used the Multifactor Dimension-
ality Reduction (MDR) model, which is a nonparametric
and genetic model-free data mining tool for nonlinear
interaction identification among genetic and environ-
mental attributes [34-36]. To adjust the results for
multiple comparisons, we performed a MDR permuta-
tion test on our data using 100,000 permutations.
Results
The allelic frequencies for the Arg16Gly polymorph-
ism were 94 (53.4%) and 82 (46.6%) for the A and G
alleles, respectively, in the asthma group and 77
(27.3%) and 205 (72.7%), respectively, in the healthy
subjects. For the Gln27Glu polymorphism, the allelic
frequencies for the C and G alleles were 118 (67.0%)
and 48 (33.0%), respectively, in the asthma group
and 93 (33.0%) and 189 (67%), respectively, in the
healthy subjects.
The polymorphisms are in Hardy-Weinberg equilib-
rium except for the Gln27Glu polymorphism, which is
not in equilibrium in the healthy subject population. The
complete genotype data and the Hardy-Weinberg equilib-
riums are shown in Table 1.
In our data, the ADRB2 polymorphisms were associ-
ated with the occurrence of asthma. For the Arg16Arg,
Gln27Gln and Gln27Glu genotypes, the risk factor odds
ratios were 6.782 (CI = 3.07 to 16.03), 2.120 (CI = 1.22 to
3.71) and 8.096 (CI = 3.90 to 17.77), respectively. For the
Gly16Gly and Glu27Glu genotypes, the odds ratios werehisms [Arg16Gly (c.46A > G) and Gln27Glu (c.79C > G)]
olymorphism χ2 p-value
CI) Gly16Gly OR (95% CI) Total
0.966) 20 (54.1%) 1.672 (0.698 - 4.003) 37 (100%) 4.674 0.322
5.454) 9 (42.9%) 0.703 (0.259 - 1.906) 21 (100%)
7.665) 10 (40%) 0.667 (0.258 - 1.726) 25 (100%)
olymorphism
CI) Glu27Glu OR (95% CI) Total
0.691) 9 (24.3%) 1.023 (0.372 - 2.812) 37 (100%) 8.285 0.082
5.197) 5 (23.8%) 0.979 (0.307 - 3.124) 21 (100%)
9.041) 6 (24%) 0.9925 (0.331 - 2.973) 25 (100%)
G) polymorphisms in combination*
CI) 2 OR (95% CI) Total
4.086) 4 (10.8%) 0.994 (0.247 - 4) 37 (100%) 1.908 0.753
2.448) 2 (9.5%) 0.827 (0.158 - 4.331) 21 (100%)
1.504) 3 (12%) 1.182 (0.271 - 5.154) 25 (100%)
Glu = Glutamic acid; A = Adenine; G = Guanine; T = Thymine; OR = Odds Ratio;
16Gly (c.46A > G) and Gln27Glu (c.79C > G) polymorphisms: (0) Arg16Arg +
ly16Gly + Glu27Glu genotype combination.
and 95% CI values were obtained using the Mild-P test and in the table the χ2
in bold.
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spectively. For more details, consult Tables 1 and 2.
The haplotype analysis showed associations between
the following polymorphisms: Arg16Arg-Gln27Gln (OR =
5.108, CI = 1.82 to 16.37), Gly16Gly-Glu27Glu (OR =
2.816, CI = 1.25 to 6.54), Arg16Gly-Gln27Glu (OR = 0.048,
CI = 0.01 to 0.14) and Gly16Gly-Gln27Glu (OR = 0.1036,
CI = 0.02 to 0.39). The complete haplotype analysis is
shown in Table 3. To confirm our data, the groups with
the highest observed frequency were analyzed in compari-
son with all of the other possible groups. The complete
group data can be found in Table 4.
All of the data and the comparisons between the groups
can be found in Figure 1.
When asthma severity was taken into account, the poly-
morphism Gln27Glu was a risk factor for severe asthma
when the Gln27Gln genotype was present (OR = 2.798,
CI = 1.099 to 6.674) and a protective factor for mild (OR =Figure 1 Complete association of the ADRB2 polymorphisms [Arg16G
(A) Gene, mRNA and protein representation; (B) polymorphism analyses (g
analyzed (red).3.063, CI = 1.037 to 9.041) and severe asthma (OR = 0.182,
CI = 0.048 to 0.691) when the Gln27Glu genotype was
present.
The MDR analysis showed evidence of an interaction be-
tween Arg16Gly and Gln27Glu as risk factors for asthma
[Testing Balance Accuracy = 0.7727; p-value = 0.0000 –
0.0010; Ratio = 0.6377] (Figure 2).
Discussion
Pharmacotherapy that is tailored to an asthmatic pa-
tient’s genotype should result in a clinically significant
increase in efficacy and reduction in adverse events and,
therefore, have an important role in disease severity [37].
The β-agonists are the most commonly used agents for
asthma treatment [1]. Polymorphisms in the ADRB2
gene have been screened and found to be associated
with altered expression, function and regulation of the
β2 receptor. These types of genetically based differencesly (c.46A > G) and Gln27Glu (c.79C > G)] with asthma risk.
reen); (C) haplotype analyzed (purple); (D) haplotype groups
Figure 2 Multifactor dimensionality reduction test for the
Arg16Gly and Gln27Glu polymorphisms in the ADRB2 gene in
Asthma patients. A. Distribution of patients according to different
genotype combinations for the clustering of Arg16Gly and Gln27Glu
polymorphisms in the ADRB2 gene. Combinations of high risk are in
gray and low risk are in white. The number in the figure represents
the patients with a given genotype combination. For example, in
the first square, 14 asthma patients (left column) and five healthy
patients (right column) have the following genotype: AA for the
Arg16Gly polymorphism and CC for the Gln27Glu polymorphism. In
this case, the first column in each square represents the asthma
patient group, and the second column represents healthy subjects.
B. Dendrogram of the polymorphism interactions with respect to
asthma presence. The same color in this case indicates linkage
between the analyzed polymorphisms. C. Graph of entropy
measuring the power of different polymorphisms and the
interactions between them for the gene analyzed to explain the
polymorphism-polymorphism association with asthma occurrence.
The association is represented by 9.87% for the Arg16Gly
polymorphism and 24.36% for the Gln27Glu polymorphism. The
interaction between the polymorphisms accounts for −9.28% of
the association. The protective genotypes in our samples are CG
(for the Gln27Glu polymorphism) and AG or GG (for the
Arg16Gly polymorphism).
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sponses to treatment with ADRB2 agonists and may
contribute to the increased mortality in select patient
populations, such as cystic fibrosis patients [31]. Sev-
eral studies have examined the ADRB2 gene as a riskfactor associated with bronchodilator response [38-40]
but not as a risk factor associated with asthma preva-
lence within a population.
The allelic frequencies of the Arg16Gly and Gln27Glu
SNPs vary with ethnicity [41,42]. The reported allele fre-
quencies for Arg16 in the Caucasian, African American
and Asian asthmatic populations were 0.39, 0.50 and
0.40, respectively, while for Gln27, the reported frequen-
cies were 0.57, 0.73 and 0.80, respectively [41]. In the
present study, the allelic frequencies of Arg16 were 0.53
in the asthma group and 0.27 in healthy subjects. For
the Gln27 allele, the allelic frequencies were 0.67 and
0.33 in the asthma group and the healthy subjects, re-
spectively. We observed that the frequencies found in
our study are similar to those found in the African
American and Caucasian populations.
The Arg16Gly and Gln27Glu polymorphisms cause
differential agonist-stimulated down-regulation of the
receptor in transfected cell systems, including human
airway smooth muscle cells [43,44]. Many previous studies
have investigated possible associations between asthma
and polymorphisms in the coding region of the ADRB2
gene, particularly the Arg16Gly and Gln27Glu SNPs;
however, these studies have yielded conflicting results
[38-40,45-48].
In the present study, associations between the Arg16Arg
and Gln27Gln genotypes and susceptibility to asthma
were observed.
The Arg16Arg genotype was more frequent in asthma
patients than in healthy subjects; the opposite correl-
ation was observed for the homozygous Glu16Glu geno-
type showing that individuals with the former genotype
have an increased susceptibility to the development of
asthma. The Gln27Gln and Gln27Glu genotypes were
indirectly related to the occurrence of asthma by the fact
that the Glu27Glu genotype had a protective effect against
asthma. Reinforcing this finding, elevated serum IgE levels
have been found in patients carrying the Arg16 and Gln27
homozygous genotypes [49].
Our results contradicted previous data from studies of
Japanese [50], African American [51] and North Indian
[52] populations but agreed with other studies of Canadian
[46], Chinese [53] and British populations [54], as well
as a study of African American children [55]. This dis-
crepancy may be the result of racial differences [48].
As expected, the results of the haplotype analysis
showed that the haplotype Arg16Arg-Gln27Gln was as-
sociated with greater risk and that the Gly16Gly-Glu27Glu
haplotype was protective. The haplotype Arg16Arg-
Gln27Gln is associated in general with a poor response to
the β2-AR agonist and low levels of β2-AR expression.
In addition, the good response to exogenous agonists is
reflected in a good response to endogenous agonists and a
protective effect against asthma [56].
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the Gly16Gly genotype conferred a decreased risk of
asthma (OR = 0.65; 95% IC = 0.41 – 1.02; p-value = 0.049),
while the Gln27Glu polymorphism was not associated
with asthma in this population [38]. In our study, we ob-
served a positive association between the Arg16Gly poly-
morphism and asthma prevalence, but the association is
weak. These data do not corroborate another study in a
Chinese population in which the Arg16Gly polymorphism
was not associated with genetic susceptibility to child-
hood asthma [39]. A contrasting study showed different
evidence: increased risk of nocturnal asthma in Egyptian
children was associated with the Gly/Gly genotype of
the Arg16Gly polymorphism (OR = 3.2; 95% CI = 1.3–7.7;
p-value = 0.03) [40]. In this Egyptian study, as in previous
studies, the Gln27Glu polymorphism did not show evi-
dence of association with asthma. In this study, the population
analyzed should be considered an important environmental
factor that interacts with the polymorphisms in the
ADRB2 gene.
Specific data can be reviewed for the polymorphism-
associated responses to short- and long-acting β2-ago-
nists. For long-acting β2-agonists, results have shown no
positive association between the Arg16Gly polymorph-
ism and bronchodilation, but the Arg16 allele was asso-
ciated with poor asthma control [57]. Contrasting results
were observed in a Chinese population study. In that study,
a significantly higher bronchodilator response was ob-
served in patients with the homozygous genotype 46A/A
(13.40% ± 3.48%) compared with those patients with the
homozygous genotype 46G/G (7.25% ± 3.11%) and the het-
erozygous genotype 46A/G (7.39% ± 3.14%) (p < 0.0001)
[58]. To determine the effects of the polymorphisms on
asthma response to bronchodilators, new studies should
be performed that include different populations, higher
sample numbers and a complete ADRB2 gene polymorph-
ism analysis. For the direct response to methacholine, no
association was found [59].
Based on the data, no consensus has been reached on
the relationship between the identified ADRB2 genetic
variations and asthma. The causal alleles that are com-
mon in most ethnic groups may have differential effects
because of interactions with the environment and/or
other genetic variants that are unique to certain ethnic
groups. The interpretation of the findings of the genetic
association studies of the ADRB2 polymorphisms is
complicated by the inadequate measurement of environ-
mental exposures and differences in the allele and haplo-
type frequencies of the ADRB2 gene and asthma severity
among different racial groups. The complexity of the
observed genotype-response effects limits their clinical
applications [60]. In this context, our study has several
strengths and limitations: our sample size may be consid-
ered small; there is no control for environmental factors;only two polymorphisms were analyzed; the Brazilian popu-
lation is admixed; and a region with a specific genotype
combination associated with risk may also be associated
with a peculiar environmental factor.
The contradictory findings in studies of literature, in-
cluding the present manuscript, may be associated by:
(i) difference in approach to clinical management be-
tween centers, (ii) criteria for diagnosis of asthma, (iii) en-
rolled population of patients (atopic and non-atopic),
(iv) population analyzed considering ethnic differences
that can alter the genotypic frequency of polymorphisms,
(v) clinical variables considered as risk factor (IgE values
changed, lung function test, time to diagnosis, evidence of
reversibility on spirometry), (vi) presence of non-reported
comorbidities, (vii) the characterization of patients taking
into account the referral center, whereas non-random
sampling for the clinical severity of asthma; (viii) technique
for evaluation of polymorphisms in the ADRB2 gene may
have, on rare occasions, erroneous results.
In conclusion, our data show that the Gln27Glu and
Arg16Gly polymorphisms of the beta 2-adrenergic re-
ceptor gene play an important role in asthma prevalence
and severity and are a potential tool for risk analysis in
our population. The results reveal the influence of each
polymorphism alone and together as a haplotype.
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